Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer

被引:3
作者
Nguyen, Thi Truc Anh [1 ]
Postlewait, Lauren M. [2 ]
Zhang, Chao [3 ]
Meisel, Jane L. [4 ]
O'Regan, Ruth [5 ]
Badve, Sunil [1 ]
Kalinsky, Kevin [4 ]
Li, Xiaoxian [1 ]
机构
[1] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Surg, Div Surg Oncol, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Pediat, Pediat Biostat Core, Atlanta, GA 30322 USA
[4] Emory Univ, Dept Hematol & Oncol, Atlanta, GA 30322 USA
[5] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA
关键词
T1 breast cancer; ER positive breast cancer; Oncotype DX; RS; Disease-free survival; metastasis; Overall survival; PATHOLOGICAL COMPLETE RESPONSE; 21-GENE EXPRESSION ASSAY; DISEASE-FREE SURVIVAL; AMERICAN-SOCIETY; RECURRENCE; THERAPY; CHEMOTHERAPY; PREDICTION; BIOMARKERS; PROGNOSIS;
D O I
10.1007/s10549-022-06530-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The management of estrogen receptor positive (ER+)/HER2- and lymph node (LN) negative breast cancers can be influenced by Oncotype DX recurrence score (RS) in the USA. However, the benefit of RS in T1 tumors (<= 1 cm) is not clear. Methods We retrieved 199 T1 ER+/HER2-/LN- breast cancer diagnosed between 1993 and 2016 that had undergone RS testing. The median follow-up time was 51 months. We examined the disease-free survival (DFS) and distant metastasis and their association with RS and other clinicopathologic features. Results Of the 199 cases, 40 were T1a (<= 0.5 cm) and 159 were T1b (> 0.5 cm to 1 cm) tumors. In the 40 T1a tumors, 11 would benefit from chemotherapy by the TAILORx study results. Of these T1a tumors, 36 were Nottingham grade 1/2, 3 were grade 3, and 1 was microinvasive carcinoma; 2 (5%) had local recurrence and 1 (2.5%) had distant metastasis to the bone. The only patient with T1a tumor (Nottingham grade 3, RS = 42) and distant metastasis to bone had received adjuvant chemotherapy. In the 159 T1b tumors, 25 would benefit chemotherapy by the TAILORx results. Of the T1b tumors, 149 were Nottingham grade 1/2 and 10 were grade 3. Nine (5.7%) had local recurrence and 2 (1.3%) had distant metastasis to bone and mediastinum, respectively. The two T1b tumors with distant metastasis had a RS 20 and Nottingham grade 2, and RS 27 and Nottingham grade 3, respectively. Both patients received adjuvant chemotherapy. In multivariate analysis of the entire cohort (T1a and T1b tumors), Nottingham tumor grade and receiving chemotherapy were significantly associated with DFS. In univariate analysis of the entire cohort, Nottingham tumor grade, receiving adjuvant chemotherapy, and RS were significantly associated with distant metastasis. Conclusion This study demonstrates that the metastatic rate of T1a and T1b ER+/HER2-/LN- breast cancer is very low. Patients with low grade (1 or 2), T1a ER+/HER2-/LN- breast cancer may not need RS for treatment decision-making; however, in patients with high-grade T1a or T1b ER+/HER2-/LN- breast cancer, RS analysis should be strongly considered.
引用
收藏
页码:509 / 516
页数:8
相关论文
共 45 条
[1]   Adjuvant therapy for breast cancer — results from the USA consensus conference [J].
Jeffrey S. Abrams .
Breast Cancer, 2001, 8 (4) :298-304
[2]   Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update [J].
Allison, Kimberly H. ;
Hammond, M. Elizabeth H. ;
Dowsett, Mitchell ;
McKernin, Shannon E. ;
Carey, Lisa A. ;
Fitzgibbons, Patrick L. ;
Hayes, Daniel F. ;
Lakhani, Sunil R. ;
Chavez-MacGregor, Mariana ;
Perlmutter, Jane ;
Perou, Charles M. ;
Regan, Meredith M. ;
Rimm, David L. ;
Symmans, W. Fraser ;
Torlakovic, Emina E. ;
Varella, Leticia ;
Viale, Giuseppe ;
Weisberg, Tracey F. ;
McShane, Lisa M. ;
Wolff, Antonio C. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1346-+
[3]   ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer [J].
Arciero, Cletus A. ;
Guo, Yi ;
Jiang, Renjian ;
Behera, Madhusmita ;
O'Regan, Ruth ;
Peng, Limin ;
Li, Xiaoxian .
CLINICAL BREAST CANCER, 2019, 19 (04) :236-245
[4]   Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study [J].
Bhargava, Rohit ;
Esposito, Nicole N. ;
O'Connor, Siobhan M. ;
Li, Zaibo ;
Turner, Bradley M. ;
Moisini, Ioana ;
Ranade, Aditi ;
Harris, Ronald P. ;
Miller, Dylan, V ;
Li, Xiaoxian ;
Moosavi, Harrison ;
Clark, Beth Z. ;
Brufsky, Adam M. ;
Dabbs, David J. .
MODERN PATHOLOGY, 2021, 34 (01) :77-84
[5]   Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features [J].
Creighton, Chad J. ;
Li, Xiaoxian ;
Landis, Melissa ;
Dixon, J. Michael ;
Neumeister, Veronique M. ;
Sjolund, Ashley ;
Rimm, David L. ;
Wong, Helen ;
Rodriguez, Angel ;
Herschkowitz, Jason I. ;
Fan, Cheng ;
Zhang, Xiaomei ;
He, Xiaping ;
Pavlick, Anne ;
Gutierrez, M. Carolina ;
Renshaw, Lorna ;
Larionov, Alexey A. ;
Faratian, Dana ;
Hilsenbeck, Susan G. ;
Perou, Charles M. ;
Lewis, Michael T. ;
Rosen, Jeffrey M. ;
Chang, Jenny C. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (33) :13820-13825
[6]   Role of RPL39 in Metaplastic Breast Cancer [J].
Dave, Bhuvanesh ;
Gonzalez, Daniel D. ;
Liu, Zhi-Bin ;
Li, Xiaoxian ;
Wong, Helen ;
Granados, Sergio ;
Ezzedine, Nadeer E. ;
Sieglaff, Douglas H. ;
Ensor, Joe E. ;
Miller, Kathy D. ;
Radovich, Milan ;
KarinaEtrovic, Agda ;
Gross, Steven S. ;
Elemento, Olivier ;
Mills, Gordon B. ;
Gilcrease, Michael Z. ;
Chang, Jenny C. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (06)
[7]   Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling [J].
Dave, Bhuvanesh ;
Granados-Principal, Sergio ;
Zhu, Rui ;
Benz, Stephen ;
Rabizadeh, Shahrooz ;
Soon-Shiong, Patrick ;
Yu, Ke-Da ;
Shao, Zhimin ;
Li, Xiaoxian ;
Gilcrease, Michael ;
Lai, Zhao ;
Cheng, Yidong ;
Huang, Tim H. -M. ;
Shen, Haifa ;
Liu, Xuewu ;
Ferrari, Mauro ;
Zhan, Ming ;
Wong, Stephen T. C. ;
Kumaraswami, Muthiah ;
Mittal, Vivek ;
Chen, Xi ;
Gross, Steven S. ;
Chang, Jenny C. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (24) :8838-8843
[8]  
Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979
[9]   Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
DeCillis, A ;
Emir, B ;
Wickerham, DL ;
Bryant, J ;
Dimitrov, NV ;
Abramson, N ;
Atkins, JN ;
Shibata, H ;
Deschenes, L ;
Margolese, RG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (22) :1673-1682
[10]   Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy [J].
Ginter, Paula S. ;
Idress, Romana ;
D'Alfonso, Timothy M. ;
Fineberg, Susan ;
Jaffer, Shabnam ;
Sattar, Abida K. ;
Chagpar, Anees ;
Wilson, Parker ;
Harigopal, Malini .
MODERN PATHOLOGY, 2021, 34 (04) :701-709